The Global Alliance for Regenerative Medicine, a world-renowned regenerative medicine clinic, announced today that it is now offering unfocused acoustic wave therapy (aka “GARM Wave”) for the treatment of musculoskeletal pain, inflamed and injured tissue, as well as for blood flow improvement. “This technology seems to bring about significant relief of patients’ pain from joint and soft tissue injuries, as well as pain form arthritis or tendonitis/tendonosis. In addition to rapid pain relief, the GARM Wave seems to contribute to reduced injury recovery time,” stated GARM’s Medical Director, Glenn C. Terry, M.D.
Read more here.
Woodstock, GA, April 19, 2016 – Tissue Regeneration Technologies, LLC (TRT) announces an Exclusive License Agreement with Acoustic Wave Cell Therapy, Inc. (AWCT), a Delaware Corporation, whereby AWCT will utilize TRT's extensive patent portfolio to develop and market low energy acoustic wave treatments for multiple internal organs and associated tissues and pathologies.
We have set up a Facebook and Twitter for the TRT community to get the latest updates!
TRT Announces Release of Patent that Opens New Doors for the Expansion of Shock Waves into Nonmedical Industries
Woodstock, GA, November 12, 2015 – Tissue Regeneration Technologies, LLC (TRT) today announces the issuance of patent number 9,060,525. With this new patent, TRT now owns the methodology of using shock wave technology to increase the amount of extract from cellular plant tissue. Modern industrial processes for extracting substances from plant cells are very inefficient and waste a lot of usable material. The use of shock waves, as patented by TRT, drastically increases the yield of such extraction processes.
ATLANTA, GA ‐‐ Cardiac Regeneration Technologies, LLC (CRT) announced that it received notification from the U.S. Internal Revenue Service (IRS) that it was approved to receive a grant in the amount of $244,000 for CRT's investment in an unprecedented myocardial regeneration therapeutic discovery project. In July 2010, the Company applied for the grant under the Qualifying Therapeutic Discovery Project.
After a determination by U.S. Department of Health and Human Services (HHS) that the project met the definition of a “qualifying therapeutic discovery project,” the IRS certified the qualifying investment and approved the award amount of $244,000. The qualified investment primarily represents 2009 research and development expenses which will continue into 2010.